השראה Pluripotency
View the full transcript and gain access to JoVE Science Education videos
Q1: What are the four Yamanaka factors and why are they important for creating iPSCs?
The four Yamanaka factors—Oct4, Sox2, cMyc, and Klf4—are transcription factors that induce pluripotency in differentiated cells. These proteins bind to regulatory sequences in genes and influence the expression of numerous genes, fundamentally changing cell identity. Their discovery revolutionized stem cell biology by enabling the reprogramming of somatic cells into pluripotent stem cells without using embryos.
Q2: How does viral transduction deliver reprogramming factors into cells?
Modified retroviruses are engineered to carry genes encoding the four Yamanaka factors. When differentiated cells are exposed to these viruses, a small fraction becomes infected with all four transcription factor-carrying viruses simultaneously. The viral genes integrate into the cell's genome, initiating dedifferentiation and eventually forming large spherical clusters of pluripotent stem cells.
Q3: What is cellular reprogramming and how does it change cell identity?
Cellular reprogramming is the process of converting an already differentiated cell into a pluripotent state by altering its gene expression patterns. Since a cell's identity is determined by the types and amounts of proteins it produces, changing which genes are expressed fundamentally transforms the cell's fate. This allows specialized cells like skin cells to regain the ability to differentiate into any cell type.
Q4: How can iPSCs be differentiated into specific cell types like heart muscle?
iPSCs are transferred to non-adherent plates where they form embryoid bodies—aggregates of pluripotent stem cells. These aggregates are then cultured in specialized medium containing serum and ascorbic acid tailored to the desired cell type. For cardiomyocytes, successful differentiation is confirmed when cells begin to beat, demonstrating functional heart muscle development.
Q5: What is tetraploid complementation and how does it demonstrate iPSC potential?
Tetraploid complementation creates an embryo with four sets of chromosomes by fusing two early embryo cells using an electric field. iPSCs are injected into the resulting blastocyst, which is then transplanted into a recipient female. Since tetraploid cells form only extraembryonic structures like the placenta, the resulting organism develops entirely from iPSCs, proving their ability to generate a complete organism.
Q6: Why do iPSC clusters help maintain pluripotency in culture?
Cluster formation creates a microenvironment similar to in vivo stem cells, which is essential for maintaining pluripotency. The three-dimensional structure and cell-cell interactions within these spherical aggregates provide signals that prevent differentiation and support the undifferentiated state, allowing iPSCs to remain capable of differentiating into any cell type.
Q7: What is the main clinical challenge preventing iPSCs from being used in therapy today?
The primary hurdle is the associated risk of cancer. Current reprogramming procedures can result in unregulated cell growth, potentially leading to malignant transformation. Although iPSCs hold enormous promise for treating degenerative disorders, more research is required to ensure their safety and efficacy before they can be safely employed in clinical practice.
Copyright © 2026 MyJoVE Corporation. All rights reserved